A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy
{"Image DocumentName": "A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy", "Image ImageDescription": "MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy. in Postmenopausal Patients with Hormone Receptor Negative Breast Cancer. Principal Investigator: Kathy D. Miller, M.D. Indiana University Medical Center. 535 Barnhill Drive, RT-473. Indianapolis, IN PD. CR, PR, SD. Day trough [MPA] < 50 ng/ml. Day trough [MPA] > 50 ng/ml. Cohort 2. Cohort 1. REGISTER. MPA 1000 mg/d. Off study. Continue. MPA 1500 mg/d. MPA 1000 mg/d + ldoCM. MPA 1500 mg/d + ldoCM.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}